The FDA held a public workshop on May 16 to explain its goals for the new pilot aimed at improving patient access to unapproved oncology drugs. The pilot is referred to as 'Project Facilitate'. Dr. Richard Pazdur, Director of FDA's Oncology Center of Excellence announced the pilot will debut at the end of May. The goal of Project Facilitate is to assist physicians and patients navigate through the single patient Investigational New Drug [IND] process, dubbed SPI. Project Facilitate FDA staff will operate a call center for oncology products, facilitate completion of the required FDA Form 3926, and identify Institutional REview Board (IRB) resources. Project Facilitate will also gather metrics on whether a company provides a drug or not, and if not, try to document the company's reason for declining a request.
FDA 'Project Facilitate' to Launch by End of May
Posted on 05/17/2019
Latest News
- Early Access to Investigational Medicines - New hope, hype or confusion? 1 year ago
- Early Access Care Enters Agreement with Veeva Systems for CDMS 1 year ago
- FDA Project Facilitate 1 year ago
- FDA 'Project Facilitate' to Launch by End of May 1 year ago
- FDA Issues Statement on Post-Trial Treatment via Expanded Access 1 year ago
- Report on Leveraging Real-World Treatment Experience from Expanded Access Protocols 1 year ago
- Scope Creep is a Potential Risk for Any EAP 2 years ago
- Rare Disease Innovation Summit 2018 - Boston 2 years ago